Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves

Five years of additional exclusivity, priority review and fast-track status are the carrots offered in legislation introduced by Rep. Phil Gingrey, R.-Ga., June 15 to entice drug makers to develop antimicrobials for drug-resistant pathogens.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet